GLP-1 for PCOS: What Women Should Know

Key Takeaways

Multiple recent studies and reviews suggest GLP-1 receptor agonists may help reduce body weight, improve insulin resistance, and support hormonal balance in women with PCOS.
A 2025 randomized controlled trial found that combining tirzepatide with metformin produced meaningful short-term improvements in metabolic and reproductive markers in overweight or obese women with PCOS.
A systematic review and meta-analysis of randomized controlled trials found GLP-1 receptor agonists were associated with reductions in BMI, testosterone levels, and fasting insulin in PCOS patients.
Current evidence indicates GLP-1 and dual GLP-1/GIP medications should generally be discontinued before or early in pregnancy due to limited safety data, and women of reproductive age should discuss contraception with their provider.
Real-world data from Poland show incretin therapy use in women with PCOS has grown substantially, reflecting rising clinical interest, though prescribing patterns and outcomes vary widely.

What is PCOS and why does metabolism matter?

PCOS (polycystic ovary syndrome) is a hormonal condition that disrupts how the body processes insulin, and that metabolic disruption sits at the center of most of its symptoms. Understanding this connection helps explain why medications that target metabolism — including GLP-1 drugs — are increasingly being studied as a treatment option for PCOS.

PCOS is one of the most common hormonal conditions in people with ovaries, affecting roughly 1 in 10 women of reproductive age. It gets its name from small fluid-filled sacs (follicles) that can appear on the ovaries, but the condition is defined by a cluster of features that don’t all have to be present at once:

Irregular or absent periods — the ovaries may not release an egg reliably each month
High androgen levels — androgens are sometimes called “male hormones,” but everyone has them; in PCOS, levels run higher than typical, which can cause acne, excess hair growth, or hair thinning
Metabolic disruption — most notably, insulin resistance

Insulin resistance is the key piece to understand. Insulin is a hormone that acts like a key, unlocking your cells so they can absorb sugar from your blood for energy. When cells stop responding well to that key, the pancreas produces more and more insulin to compensate. Those high insulin levels then signal the ovaries to produce extra androgens. This hormonal ripple effect drives many of PCOS’s most frustrating symptoms, including irregular cycles and difficulty with weight, as a recent evidence review explains.

Why does this matter for weight? Insulin resistance makes it harder for the body to use stored fat for energy and can increase appetite signals. This creates a cycle: weight gain worsens insulin resistance, which worsens PCOS symptoms, which can make weight management harder. Research published in a systematic review and meta-analysis confirms that metabolic factors — including body weight and insulin sensitivity — are central targets in PCOS treatment.

This is why metabolism matters so much in PCOS care. Addressing insulin resistance doesn’t just affect the number on the scale — it can influence hormone balance, cycle regularity, and overall wellbeing. A real-world cohort study found that incretin-based therapies (the medication class that includes GLP-1 drugs) are increasingly being used in women with PCOS, reflecting growing clinical interest in targeting this metabolic root cause.

This content is for general informational purposes only and is not medical advice. It does not replace the guidance of a qualified healthcare professional. Always consult your doctor or another licensed provider before starting, stopping, or changing any treatment.

How do GLP-1 and incretin-based medications work?

GLP-1 and incretin-based medications work by mimicking natural gut hormones that your body releases after eating—hormones that signal fullness, slow digestion, and help control blood sugar. By amplifying these signals, these medications reduce appetite and support weight loss through biology, not willpower.

What are incretins?

Incretins are hormones released by your gut when you eat. The two most important are:

GLP-1 (glucagon-like peptide-1) — released mainly from the small intestine; signals fullness to your brain, slows gastric emptying, and prompts the pancreas to release insulin when blood sugar rises
GIP (glucose-dependent insulinotropic polypeptide) — works alongside GLP-1 to support insulin release and may play a role in fat metabolism

In people with obesity or insulin resistance, these hormone signals are often weaker or shorter-lived than normal. GLP-1 receptor agonist medications (like semaglutide) and dual GLP-1/GIP receptor agonists (like tirzepatide) strengthen these signals, as described in this evidence map of incretin medications.

How these medications work in your body:

Slow gastric emptying — food moves more slowly from your stomach to your intestines, extending feelings of fullness
Reduce appetite signals in the brain — the medication acts on hunger-regulating brain regions to lower eating drive
Improve insulin sensitivity — they help your body use insulin more effectively, particularly important for insulin resistance, as reviewed in this systematic review and meta-analysis
Lower blood sugar safely — the insulin-stimulating effect activates only when blood sugar is elevated, reducing hypoglycemia risk

GLP-1 vs. dual GLP-1/GIP medications:

Feature	GLP-1 agonists (e.g., semaglutide)	Dual GLP-1/GIP agonists (e.g., tirzepatide)
Targets	GLP-1 receptor only	GLP-1 + GIP receptors
Appetite reduction	Yes	Yes, potentially stronger
Blood sugar support	Yes	Yes
Evidence base	Extensive	Growing rapidly

Tirzepatide Research has shown meaningful reductions in body weight and improvements in metabolic markers, as seen in this randomized controlled trial in women with PCOS. The benefits of incretin therapy on metabolic health remain an active area of Research.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

What does the Research say about GLP-1 for PCOS?

Early Research suggests GLP-1 medications may offer meaningful benefits for people with PCOS (polycystic ovary syndrome — a hormonal condition that affects ovulation, metabolism, and androgen levels) beyond weight loss alone. However, evidence is still emerging, and results vary between individuals.

Weight and metabolic changes

A systematic review and meta-analysis found that GLP-1 receptor agonists significantly reduced body weight, BMI, waist circumference, and fasting insulin levels in people with PCOS compared to control groups. The same analysis also showed improvements in insulin resistance, a core driver of PCOS symptoms for many people.

Hormonal and reproductive changes

A literature review on incretin therapy and ovarian function found that GLP-1 medications may help lower androgen levels (hormones like testosterone that are often elevated in PCOS) and support more regular ovulation. A randomized controlled trial in Chinese women with PCOS found that combining tirzepatide (a dual GLP-1/GIP receptor agonist) with metformin improved menstrual regularity and hormone levels over the treatment period. An evidence map of incretin-based medications in PCOS noted improvements in ovulation and cycle regularity across multiple studies, though most trials remain small and short-term.

Growing clinical use

A real-world cohort study from Poland found that GLP-1 and related incretin-based therapies are being prescribed to women with PCOS at increasing rates, often alongside metformin — reflecting growing clinical interest as formal guidelines develop.

Fertility and pregnancy considerations

Because GLP-1 medications may improve ovulation, pregnancy can become possible sooner than expected, even with previously irregular cycles. A clinical perspectives review emphasizes that contraception planning is an important conversation to have with your doctor before or during treatment. Current safety data on GLP-1 use during pregnancy is limited, and most guidelines recommend stopping these medications before conception.

Most studies to date are short-term and small. Talk with your healthcare provider about whether a GLP-1 medication is appropriate for your situation.

What are the potential risks and safety concerns for women?

GLP-1 medications carry specific risks for women that warrant careful consideration before starting treatment. Most critically, these drugs are not considered safe during pregnancy, and they may unexpectedly increase fertility in some women. Here is what current evidence shows.

Pregnancy: a clear caution

GLP-1 medications should be stopped before becoming pregnant. A systematic review of maternal and fetal outcomes found that safety data during pregnancy and breastfeeding remain limited. Current guidance recommends discontinuing these drugs before conception — typically at least one to two months before trying to conceive — because effects on a developing baby are not yet well understood (systematic review, PMID 41885132). If you are pregnant, planning to become pregnant, or breastfeeding, talk to your doctor before starting or continuing a GLP-1 medication.

Unexpected pregnancy: a real possibility

GLP-1 medications can improve ovulation in women with irregular or absent periods — particularly those with polycystic ovary syndrome (PCOS), a hormonal condition affecting ovulation and fertility (literature review, PMID 42278283).
Some women who believed they were unlikely to conceive may become fertile again while on these medications (clinical perspectives, PMID 41860479).
GLP-1 drugs may also affect how well oral contraceptives are absorbed, since these medications slow digestion. Reduced absorption could lower the pill’s effectiveness (clinical perspectives, PMID 41860479).

What this means practically: Women who do not want to become pregnant should discuss reliable contraception options — such as non-oral methods — with their healthcare provider when starting a GLP-1 medication.

Common side effects

The most frequently reported side effects — nausea, vomiting, and digestive discomfort — are well documented in GLP-1 studies (evidence map, PMID 42106472). These effects are generally most noticeable when starting the medication or increasing the dose and often ease over time.

The bottom line

These risks are manageable for many women but require an honest conversation with a qualified healthcare provider — especially regarding pregnancy intentions and contraception choices.

Disclaimer: This content is for general informational purposes only and is not medical advice. It does not replace consultation with a licensed healthcare professional. Never start, stop, or change a medication based on information you read here.

What should women know about GLP-1 medications and fertility or pregnancy?

GLP-1 medications may improve some aspects of reproductive health in women — particularly those with polycystic ovary syndrome (PCOS) — but they are not recommended during pregnancy, and women who could become pregnant need specific guidance before starting or continuing them.

If you have PCOS, GLP-1s may help regulate your cycle

PCOS (polycystic ovary syndrome) is a hormonal condition that disrupts ovulation and causes irregular periods. Research suggests GLP-1 medications can help:

A systematic review and meta-analysis found that GLP-1 receptor agonists improved menstrual regularity and reduced androgen levels (male-type hormones often elevated in PCOS) in women with the condition — systematic review & meta-analysis
A literature review found that incretin-based therapies (the drug class GLP-1s belong to) showed benefits for ovarian function, including improvements in ovulation patterns — literature review on ovarian function
A randomized controlled trial in women with PCOS found that combining tirzepatide (a dual GLP-1/GIP medication) with metformin improved hormonal and metabolic markers — randomized controlled trial

Better cycle regulation can increase the chance of unplanned pregnancy

If GLP-1 medications help restore regular ovulation, your fertility may increase — even if you previously had irregular periods and assumed pregnancy was unlikely. Clinical guidance recommends that women using GLP-1s employ reliable contraception if they do not want to become pregnant — clinical perspectives on fertility & contraception.

GLP-1 medications are not considered safe during pregnancy

Current evidence does not support using GLP-1 medications if you are pregnant or trying to conceive:

A systematic review of maternal, fetal, and neonatal outcomes found that safety data for GLP-1 and dual GLP-1/GIP medications during pregnancy and breastfeeding remains limited, and the review could not confirm these drugs are safe in those periods — systematic review of pregnancy safety
Clinical guidance recommends stopping GLP-1 medications before attempting conception — clinical perspectives on fertility & contraception

Key practical takeaways

Tell your prescriber if you are trying to conceive, pregnant, or breastfeeding
Use effective contraception while on a GLP-1 medication if pregnancy is not your goal
Do not stop or continue a GLP-1 medication during pregnancy without talking to your doctor first

This content is for general information only and is not medical advice. Talk with a qualified healthcare provider about your personal situation before making any changes to your medication.

What questions should you ask your healthcare provider?

The most important step before — and during — GLP-1 therapy is an open, ongoing conversation with your healthcare provider. Coming prepared with specific questions helps you get care tailored to your whole health picture, not just your weight.

Starting a new medication works best when you and your provider are aligned. Below are practical questions to bring to your next appointment, organized by topic.

Before you start

-“Is a GLP-1 medication right for me given my full health history?” These medications affect more than weight—they influence hormones, blood sugar, and reproductive health. A systematic review and meta-analysis found that GLP-1 receptor agonists improved several metabolic markers in people with polycystic ovary syndrome (PCOS), which means your provider needs the full picture to weigh benefits against risks.

“Do any of my current medications interact with this one?” For example, combining a GLP-1 with metformin (a common diabetes and PCOS medication) is being actively studied. A randomized controlled trial found changes in weight and hormone levels with short-term combined use—your provider can advise whether that combination is appropriate for you.

-“What side effects should I watch for, and when should I call you?” Nausea and digestive discomfort are common, especially early on. Knowing your provider’s threshold for a check-in call removes guesswork.

If you are pregnant, trying to conceive, or breastfeeding

“Should I stop this medication before trying to get pregnant?” Current guidance leans toward stopping GLP-1 medications before conception, though evidence is still developing. A systematic review of maternal and fetal outcomes found limited safety data for use during pregnancy and breastfeeding, making this an essential conversation with your provider.
“How might this medication affect my fertility or menstrual cycle?” Research suggests GLP-1 medications may support more regular ovulation in some people, particularly those with PCOS, as outlined in a scientific literature review on ovarian function. This also means your contraception needs may change—ask your provider directly.

-“Do I need to adjust my birth control while on this medication?” GLP-1 medications may affect how the body absorbs oral contraceptives. A clinical perspectives review highlights this as an area requiring provider guidance.

Ongoing check-ins

“How will we know if this medication is working for me?” Ask what specific measurements your provider will track—weight, blood sugar, hormone levels, or cycle regularity—and how often.
“What’s the plan if I want to stop or switch medications?” Understanding the off-ramp before you need it reduces stress later.

This content is for general information only and is not a substitute for personalized medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

FAQ

Are GLP-1 medications approved specifically for PCOS?

As of the most recent Research reviewed here, GLP-1 receptor agonists are not specifically approved by regulatory agencies for treating PCOS. They are approved for type 2 diabetes and/or chronic weight management in eligible adults. Their use in PCOS is considered off-label in most contexts, and clinical guidelines are still evolving. Always consult a qualified healthcare provider about what is appropriate for your individual situation.

Can GLP-1 medications improve menstrual regularity or ovulation in PCOS?

Some studies included in recent reviews suggest incretin-based therapies may support improvements in menstrual cycle regularity and ovarian function in women with PCOS, potentially linked to weight loss and reduced insulin resistance. However, evidence is still emerging, study sizes are often small, and results are not guaranteed for any individual. Speak with your gynecologist or endocrinologist for personalized guidance.

Is tirzepatide different from semaglutide for PCOS?

Tirzepatide is a dual GLP-1/GIP receptor agonist, meaning it activates two hormone pathways, while semaglutide activates only the GLP-1 pathway. A 2025 randomized controlled trial studied tirzepatide combined with metformin in women with PCOS and found short-term improvements in metabolic and reproductive markers. Research directly comparing these medications specifically for PCOS outcomes is limited, and neither is approved specifically for PCOS.

Should I stop a GLP-1 medication if I become pregnant or am trying to conceive?

A 2025 systematic review of maternal, fetal, and neonatal outcomes found that safety data on GLP-1 and dual GLP-1/GIP receptor agonists during pregnancy and lactation remain limited. Current guidance generally recommends discontinuing these medications before conception or upon discovering pregnancy. Because GLP-1 medications may also affect contraceptive absorption (particularly oral pills) due to slowed gastric emptying, women of reproductive age should discuss contraception and family planning with their healthcare provider before and during treatment.

Can GLP-1 medications be combined with metformin for PCOS?

Research, including a 2025 randomized controlled trial in Chinese women with PCOS, has explored combining tirzepatide with metformin and reported short-term improvements in weight and reproductive hormone levels. A case report also described combined GLP-1 receptor agonist and SGLT2 inhibitor therapy in a patient with obesity, PCOS, and type 2 diabetes. Combination approaches are an active area of study, but decisions about combining medications must be made by a qualified healthcare provider based on your full medical history.

Where can I find a provider knowledgeable about GLP-1 medications and PCOS?

Endocrinologists, reproductive endocrinologists, and gynecologists with experience in metabolic health are often well-positioned to discuss incretin-based therapies in the context of PCOS. You can ask your primary care provider for a referral, or search for specialists through professional medical society directories. Be sure to bring a list of your current medications, symptoms, and any questions about your reproductive goals to the appointment.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.